Innovation in bone healing and tissue repair
  • slidebg1
  • slidebg1
  • slidebg1
  • slidebg1
  • slidebg1
Kuros Biosciences AG is a Swiss-based company focused on the development of innovative products for tissue repair and regeneration.

Kuros has developed a pipeline of clinical and preclinical programmes at various stages of development and generated significant data in a number of indications and applications. The most advanced programmes are targeting commercially attractive opportunities in certain segments of the tissue repair and regeneration space, notably sealants and orthobiologics. In addition to many years of substantial preclinical work, Kuros Biosurgery has now enrolled over 600 patients in multi-national clinical trials, generating promising safety and efficacy in a number of indications.

Latest News
16 Nov 17
Kuros announces management changes
Kuros Biosciences AG announced today the promotion of Dr. Joost de Bruijn to Chief Executive Officer (CEO), effective December 4, 2017. Dr. de Bruijn is co-founder and current managing director of Kuros Biosciences BV (formerly known as... READ MORE


26 Sep 17
Kuros Biosciences Reports Financial Results for First Half-Year of 2017
Kuros, an orthobiologic company with several commercial-stage products, today announced the financial figures for the first six months of 2017. The Company reported significantly lower net operating costs of CHF 7.5 million and a... READ MORE


Kuros Biosciences AG
Wagistrasse 25, 8952 Schlieren, Switzerland
Tel: +41 44 733 47 47   Fax: +41 44 733 47 40   Email: info@kuros.ch

About Kuros

  1. Overview
  2. Executive Committee
  3. Board

Products

  1. Pipeline
  2. Orthobiologics
    Fracture repair
    KUR-111
    KUR-113
    MagnetOs
    Spinal fusion
    KUR-113
    MagnetOs
    Solitary Bone Cysts
    KUR-112
  3. Sealants
    Neuroseal (KUR-023)

Technologies

  1. Overview
  2. Surface Science Technology
  3. Synthetic Cross-Linking Technology
  4. Fibrin-Based
  5. Immune Modulation
  6. Publications

Partnerships

  1. Collaborations
  2. Business development

Investors

  1. Share price
  2. Regulatory filings
  3. Reports & presentations
  4. Calendar
  5. Corporate governance
  6. Stay informed

News

  1. Press releases
  2. Conferences & Events

Contact

  1. Location
Kuros Biosciences AG is a Swiss-based company focused on the development of innovative products for tissue repair and regeneration.

Kuros has developed a pipeline of clinical and preclinical programmes at various stages of development and generated significant data in a number of indications and applications. The most advanced programmes are targeting commercially attractive opportunities in certain segments of the tissue repair and regeneration space, notably sealants and orthobiologics. In addition to many years of substantial preclinical work, Kuros Biosurgery has now enrolled over 600 patients in multi-national clinical trials, generating promising safety and efficacy in a number of indications.

Latest News
16 Nov 17
Kuros announces management changes
Kuros Biosciences AG announced today the promotion of Dr. Joost de Bruijn to Chief Executive Officer (CEO), effective December 4, 2017. Dr. de Bruijn is co-founder and current managing director of Kuros Biosciences BV (formerly known as... READ MORE


26 Sep 17
Kuros Biosciences Reports Financial Results for First Half-Year of 2017
Kuros, an orthobiologic company with several commercial-stage products, today announced the financial figures for the first six months of 2017. The Company reported significantly lower net operating costs of CHF 7.5 million and a... READ MORE